Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: Post hoc analyses from three clinical trials

Clinical Transplantation

Volumn 21, Issue 1, 2007, Pages 117-125

  Pietruck, Frank ^a   Budde, Klemens ^b   Salvadori, Maurizio ^c   Sollinger, Hans ^d   Bourbigot, Bernard ^e   Gentil, Miguel Angel ^f   Oppenheimer, Frederic ^g  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e SERVICE DE RHUMATOLOGIE   (France)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Diabetes; Efficacy; Enteric coated mycophenolate sodium; Kidney transplantation; Mycophenolate mofetil; Myfortic ; Safety

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABNORMAL LABORATORY RESULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; BLOOD DISEASE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHATIC SYSTEM DISEASE; MAINTENANCE THERAPY; META ANALYSIS; MORBIDITY; MYCOSIS; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTEMATIC REVIEW; VIRUS INFECTION;

ADULT; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDIES; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 33846701184     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00615.x     Document Type: Article

References (30)

1. Arns W, Breuer S, Choudhury S et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005: 19: 199.
2. Sollinger H. Enteric-coated mycophenolate sodium: Therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc 2004: 36 (Suppl. 2): 517S.
3. Salvadori M, Holzer H, de Mattos A et al. ERL B301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.
4. Salvadori M. ERL B301 Study Group. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients. Transplant Proc 2005: 37: 909.
5. Salvadori M, Holzer H, Civati G et al.; ERL B301 Study Group. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS, myfortic ®) is safe in kidney transplant patients. Clin Nephrol 2006: 66: 112.
6. Abbud-Filho M, Giron F, Hernandez E et al.; Myproms Latam Study Group. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study. Transplant Proc 2004: 36: 1647.
7. Budde K, Curtis J, Knoll G et al.; ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004: 4: 237.
8. Nashan B, Ivens K, Suwelack B, Arns W, Abbud Filho M; myPROMS DE02 Study Group; LA01 Study Group. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: Preliminary results from the myfortic prospective multicenter study. Transplant Proc 2004: 36 (Suppl. 2): 521S.
9. Budde K, Knoll G, Curtis J et al. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. Transplant Proc 2005: 37: 912.
10. Massari P, Duro-Garcia V, Giron F et al.; myPROMS LatAm Study Group. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005: 37: 916.
11. Budde K, Knoll G, Curtis J et al.; ERL B302 Study Group. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic ®). Clin Nephrol 2006: 66: 103.
12. Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006: 81: 1290.
13. Hergesell O, Zeier M. Underdiagnosis of diabetes mellitus in chronic dialysis patients on the renal transplant waiting list. Transplant Proc 2003: 35: 1287.
14. Viberti G. Diabetes mellitus: A major challenge in transplantation. Transplant Proc 2001: 33 (Suppl. 5A): 3S.
15. Wynn JJ, Distant DA, Pirsch JD et al. Kidney and pancreas transplantation. Am J Transplant 2004: 4 (Suppl. 9): 72.
16. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991: 20: 477.
17. Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol 2003: 98: 264.
18. Pescovitz MD, Guasch A, Gaston R et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients Am J Transplant. 2003: 3: 1581.
19. Van Hest RM, Mathot RA, Vulto AG, Le Meur Y, van Gelder T. Mycophenolic acid in diabetic renal transplant recipients: Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004: 26: 620.
20. Akhlaghi F, Patel CG, Zuniga XP, Halilovic J, Preis IS, Gohh RY. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 2006: 28: 95.
21. Van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006: 17: 871.
22. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
24. Budde K, Zeier M, Cohen D, Kirchherr B, for the my PROMS Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric-coated mycophenolate sodium? Am J Transplant 2005: 5 (Suppl. 11): 464 [abstract].
25. Legendre C, Rostaing L, Kirchherr B, for the my PROMS Study Group. Tolerability of enteric-coated mycophenolate sodium (EC-MPS) in combination with Neoral ® and steroids in de novo kidney transplant recipients: A 12 month prospective trial. Am J Transplant 2005: 5 (Suppl. 11): 464 [abstract].
26. Pietruck F, Abbud-Filho M, Vathsala A et al., for the my PROMS Study Group. Conversion to enteric-coated mycophenolate sodium (EC-MPS) from MMF in stable renal transplant recipients: Results of a large multicenter international study. Transplant Int 2005: 18 (Suppl. 1): 51 [abstract].
27. Cohen D, Zeier M, Legendre C, Budde K, Rostaing L. Pooled analysis of three prospective, 12-month, multicenter studies of enteric-coated mycophenolate sodium (myfortic ®) in de novo renal transplant patients. Transplantation 2006: 82 (1 Suppl. 2): 503 [abstract].
28. Budde K, Glander P, Diekmann F et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004: 5: 1333.
29. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 2001: 24: 1044.
30. David KM, Morris JA, Steffen BJ, Chi-Burris KS, Gotz VP, Gordon RD. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005: 19: 279.